Jazz Pharmaceuticals plc
JAZZ
$167.10
$0.390.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.14% | 4.52% | 5.76% | 6.12% | 5.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.14% | 4.52% | 5.76% | 6.12% | 5.23% |
| Cost of Revenue | 13.19% | 11.33% | 13.50% | 10.56% | -0.57% |
| Gross Profit | 3.23% | 3.85% | 5.01% | 5.69% | 5.84% |
| SG&A Expenses | 20.00% | 17.61% | 15.95% | 8.31% | 8.48% |
| Depreciation & Amortization | 3.85% | 2.51% | 1.92% | 3.13% | 4.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.13% | 6.46% | 7.21% | 6.28% | 6.09% |
| Operating Income | -15.80% | -4.19% | -1.12% | 5.49% | 1.93% |
| Income Before Tax | -277.48% | -273.25% | 51.88% | 58.92% | 470.92% |
| Income Tax Expenses | -403.44% | -8.24% | -30.12% | 23.75% | 64.36% |
| Earnings from Continuing Operations | -179.56% | -202.51% | 45.77% | 35.02% | 479.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -179.56% | -202.51% | 45.77% | 35.02% | 479.28% |
| EBIT | -15.80% | -4.19% | -1.12% | 5.49% | 1.93% |
| EBITDA | -6.32% | -0.40% | 0.71% | 4.50% | 2.96% |
| EPS Basic | -179.96% | -205.13% | 49.57% | 38.88% | 504.09% |
| Normalized Basic EPS | -13.38% | 6.04% | 12.81% | 19.44% | 14.99% |
| EPS Diluted | -185.51% | -215.61% | 54.76% | 43.64% | 710.31% |
| Normalized Diluted EPS | -8.35% | 15.06% | 19.26% | 30.17% | 16.42% |
| Average Basic Shares Outstanding | -2.41% | -2.78% | -2.54% | -2.29% | -1.67% |
| Average Diluted Shares Outstanding | -7.44% | -9.62% | -7.86% | -10.91% | -5.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |